Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunesis Obtains Milestone Payment From Biogen Idec
Sunesis has received a $1.5 million milestone payment from Biogen Idec for the selection of a Raf kinase inhibitor development candidate. It is intended for the treatment of
Sunesis has received a $1.5 million milestone payment from Biogen Idec for the selection of a Raf kinase inhibitor development candidate. It is intended for the treatment of
Baxter and Flamel Technologies have entered into an agreement to formulate controlled release applications of blood clotting factor replacement therapies, using Flamel’s Medusa Technology. The two companies will
Humanetics has announced that the results of a preliminary phase IIA clinical trial suggest that a new Alzheimer’s drug NIC5-15, is safe for daily use and that cognitive
Teva Pharmaceutical has received the FDA approval for its New Drug Application (NDA) of Plan B One-Step emergency contraception (levonorgestrel tablet, 1.5mg). With new Plan B One-Step, women
IVAX has signed a distribution agreement with Augurix for Simtomax Blood Drop, a test that diagnoses celiac disease in all patients. As part of the agreement, IVAX will
AxoGen is beginning full distribution of Avance Nerve Graft. Its a proprietary human tissue product for use in the reconstruction of damaged peripheral nerves to all surgeons who
Elan and Transition Therapeutics has presented phase 1 data, which demonstrated that treatment with ELND005 (scyllo-inositol) has achieved desired concentrations in human brain tissue and cerebrospinal fluid. ELND005
Inovio’ SynCon H1N1 influenza DNA vaccines has achieved protective antibody responses against H1N1 swine influenza virus, in 100% of pigs immunized with a two-dose vaccine regimen. In the
CytRx’ investigational cancer drug, INNO-206 has caused destruction of implanted tumors in an experimental animal model of breast cancer. It performed considerably better than the broadly used chemotherapeutic
Bayer Schering has reported positive results for the phase-II study of the novel positron emission tomography (PET) tracer florbetaben (BAY 94-9172). The study showed that patients with Alzheimer’s